Prostate cancer, version 3.2012 Journal Article
| Authors: | Mohler, J. L.; Armstrong, A. J.; Bahnson, R. R.; Boston, B.; Busby, J. E.; D'Amico, A. V.; Eastham, J. A.; Enke, C. A.; Farrington, T.; Higano, C. S.; Horwitz, E. M.; Kantoff, P. W.; Kawachi, M. H.; Kuettel, M.; Lee, R. J.; MacVicar, G. R.; Malcolm, A. W.; Miller, D.; Plimack, E. R.; Pow-Sang, J. M.; Roach, M. 3rd; Rohren, E.; Rosenfeld, S.; Srinivas, S.; Strope, S. A.; Tward, J.; Twardowski, P.; Walsh, P. C.; Ho, M.; Shead, D. A. |
| Article Title: | Prostate cancer, version 3.2012 |
| Abstract: | The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; review; salvage therapy; advanced cancer; diarrhea; drug withdrawal; hypertension; side effect; antineoplastic agents; bone metastasis; cancer patient; lymph node metastasis; lymph node dissection; clinical practice; edema; metastasis; practice guideline; high risk patient; docetaxel; coughing; prostatic neoplasms; hypokalemia; prostatectomy; heart failure; mitoxantrone; urinary tract infection; androgen antagonists; urinary frequency; brachytherapy; taxoids; hot flush; external beam radiotherapy; abiraterone acetate; antiandrogen; ketoconazole; orchiectomy; testosterone blood level; heart arrhythmia; dyspepsia; joint swelling; androgen deprivation therapy; testosterone; zoledronic acid; upper respiratory tract infection; castration resistant prostate cancer; randomized controlled trial (topic); urosepsis; phase 2 clinical trial (topic); phase 1 clinical trial (topic); denosumab; cabazitaxel; sipuleucel t; androstadienes; nocturia; tissue extracts |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 10 |
| Issue: | 9 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2012-09-01 |
| Start Page: | 1081 |
| End Page: | 1087 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 22956807 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 November 2012" - "Source: Scopus" |
